Botanix Pharmaceuticals (ASX:BOT) is currently expected to have little to no impact from the executive order by Trump to lower drug prices in the US, Euroz Hartley said in a Tuesday note.
The research firm noted that the company's drug Sofdra is only approved and sold in the US, lacking an international price for reference.
Provisions in the order related to antitrust enforcement, pharmaceutical exports, or unsafe drug approvals are not relevant to the company or Sofdra, the note added.
Euroz Hartleys maintained Botanix Pharmaceuticals' buy rating with a price target of AU$0.80.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.